Back to top
more

Bayer (BAYRY)

(Delayed Data from OTC)

$14.02 USD

14.02
667,628

-0.09 (-0.64%)

Updated Aug 28, 2026 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.80%
2Buy18.13%
3Hold10.19%
4Sell5.73%
5Strong Sell3.17%
S&P50011.53%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (101 out of 248)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Is Medpace (MEDP) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Medpace (MEDP) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.

Zacks Equity Research

REGN Stock Up on Q3 Earnings Beat, Eylea HD Sales Increase

by Zacks Equity Research

Regeneron's Q3 earnings beat forecasts as strong Dupixent profits and rising Eylea HD sales offset a decline in its flagship Eylea brand.

Zacks Equity Research

Novartis Lags Q3 Earnings, Announces $12B Avidity Biosciences Acquisition

by Zacks Equity Research

Novartis' Q3 profit rose on 8% higher sales led by Kisqali, Kesimpta and Pluvicto, as new acquisitions expand its neuroscience and cardiovascular reach.

Zacks Equity Research

Sanofi Q3 Earnings Beat, Dupixent Drives Growth as Vaccines Decline

by Zacks Equity Research

Sanofi's Q3 earnings top forecasts as Dupixent surges past EUR 4B in sales, offsetting weakness in vaccines.

Zacks Equity Research

NVS Reports Positive Late-Stage Data on Kidney Disease Drug

by Zacks Equity Research

Novartis' Fabhalta shows strong phase III results in slowing IgA nephropathy progression, paving the way for full FDA approval in 2026.

Zacks Equity Research

JNJ Beats on Q3 Earnings, Ups Sales View, to Spin-off Orthopaedics Unit

by Zacks Equity Research

J&J tops Q3 forecasts, lifts 2025 sales outlook and plans to spin off its struggling Orthopaedics business.

Zacks Equity Research

Is Bayer (BAYRY) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Bayer Aktiengesellschaft (BAYRY) and Biorestorative Therapies, Inc. (BRTX) have performed compared to their sector so far this year.

Zacks Equity Research

BAYRY Begins Phase I Study With KQB548 in KRAS-Mutated Cancers

by Zacks Equity Research

Bayer and Kumquat launch a phase I study of KQB548, aiming to target various KRAS G12D-mutated tumors like pancreatic, colorectal and lung cancer.

Zacks Equity Research

Bayer Reports Positive Data on Cell Therapy for Parkinson's Disease

by Zacks Equity Research

BAYRY's subsidiary BlueRock reports 36-month data showing its Parkinson's therapy bemdaneprocel remains safe and effective in easing motor symptoms.

Kinjel Shah headshot

3 Large Drug Stocks to Watch as Industry Recovers After PFE-Trump Deal

by Kinjel Shah

Pfizer's landmark pricing deal with Trump sparks a pharma rally as J&J, Bayer and Novartis emerge as strong contenders for inclusion in one's portfolio.